Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing products for patients with cancer. The Company has created a targeted anti-cancer agent designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its pipeline includes two clinical-stage programs. ON 123300 product candidate is a multi-kinase inhibitor targeting cyclin dependent kinase (CDK 4/6) and other tyrosine kinasesto to drive tumor proliferation. Its another product candidate Oral Rigosertib in combination with a PD-1 inhibitor targeting patients with K-Ras mutated non-small cell lung cancer (NSCLC).
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)